HTS Biosystems, a developer of high throughput bio-analytical systems, reported that its recently released Flexchip Kinetic Analysis System is providing researchers with important new capabilities.

Significant breakthroughs for antibody and protein interaction research at Genentech, a leading biotechnology company and the University of Utah Centre for Biomolecular Interaction Analysis are being made as a result of the enabling capabilities of the Flexchip system.

The Flexchip Kinetic Analysis System represents a first-to-market, real-time, label-free detection array platform positioned for the fast growing protein interaction and biochip array markets. HTS's proprietary Grating coupled surface plasmon resonance (GCSPR) and advanced disposable plastic chip technologies combine to make the Flexchip a powerful research platform, the company release said.

"We've been using the Flexchip, having had one of the early prototypes and now the commercial system, for three years and it has allowed us to enter new dimensions in experiments that previously could not be realized," said Prof. David Myszka, from the University of Utah and director of The Centre For Biomolecular Interaction Analysis. "The new approach and throughput capabilities of the Flexchip enable us to look at hundreds of reactants simultaneously, which is critical to facilitating breakthroughs in antibody research and biotherapeutic discovery that prior systems could not provide," concluded Myszka.

"We have only touched upon the potential of the Flexchip systems capabilities," Dr. Sachdev Sidhu, senior Scientist Protein Engineering at Genentech said adding, "Since we received the system we have found the ability to test natural proteins and protein interactions surpassed what we were able to do and are further along in our cellular pathway studies than we thought we would be."

"We are very excited with the new applications and efficiencies that our customers are discovering with our system," Enrico Picozza COO/CTO said adding, "The Flexchip represents cutting edge proprietary technology, optimized over many years of development, which has now delivered capabilities never before obtained. With its current features and future application expansion, the Flexchip will remain a valuable platform for meeting the needs of the biotherpetic development and protein research markets."

HTS is a recognized developer of next-generation, high-throughput bio-analytical systems and related consumables for the rapidly expanding proteomics, biodefense and medical diagnostic markets.